D. Gary Gilliland, MD, PhD

D. Gary Gilliland, MD, PhD


1975 B.S University of California, Davis (Bacteriology)
1980 Ph.D. University of California, Los Angeles (Microbiology)
Dr. R. John Collier, Advisor
1984 M.D. University of California, San Francisco


As Director of the Fred Hutch/University of Washington Cancer Consortium and Principal Investigator of the Cancer Center Support Grant, Dr. Gilliland maintains oversight to successfully carry out the proposed research project. The Consortium brings together more than 450 members with research interests in basic, clinical and public health sciences related to cancer. The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration among the partner institutions in the cancer research disciplines of basic, clinical and public health sciences affords new opportunities to reduce suffering and mortality from cancer. His personal research has focused on understanding the genetic basis of human cancer, with an emphasis on hematologic malignancies, and translating these insights into improvements in patient outcomes.

Fred Hutch President and Director Dr. Gary Gilliland discusses his bold vision for cancer care and curative therapies. To arrange an interview with Dr. Gilliland, please contact media relations at (206) 667-2210 or email media@fredhutch.org.

Research, Teaching and Clinical Contributions

Prior to joining Fred Hutch, Dr. Gilliland's research efforts while at Harvard focused initially on the genetic basis of hematologic malignancies, with a goal of utilizing insights from these studies for clinical translational purposes. His research contributions have included the positional cloning of a spectrum of disease alleles associated with myeloproliferative disease, acute leukemias and myelodysplastic syndromes that have enabled molecularly targeted therapies for these disorders. These mutant genes have been characterized in biochemical, cell culture and murine models of leukemia. Transforming properties have been characterized both for signal transduction and for transcriptional activation properties. Using murine models, specific inhibitors have been developed, and these have been translated into therapeutic trials. His work has thus spanned the spectrum of bench to bedside research.

Awards and Honors

1978 Sydney C. Rittenberg Award for Outstanding Accomplishment in Graduate Studies, Department of Microbiology, UCLA
1979-1980 NCI Postdoctoral Fellowship, UCLA
1981-1982 President's Undergraduate Fellowship, UCSF
1984 Gold-Headed Cane Award, UCSF
1988-1989 Malcolm B. Hecht Fellow in Hematology, Brigham and Women's Hospital
1990-1991 Julian and Eunice Cohen Scholar in Medicine, Brigham and Women's Hospital
1990-1992 Jose Carreras Scholar Award, American Society of Hematology
1991-1993 Harvard-Sandoz Scholar in Medicine
1995-2000 Stephen Birnbaum Scholar, Leukemia Society of America
2000 Abelson Lecturer, University of Washington, Seattle, WA
2001 James Kuebel Memorial Lecturer, Washington University, St. Louis
2002 Huntsman Cancer Institute Distinguished Lectureship, University of Utah
2002 Helen Ranney Lecturer, Medical Grand Rounds, UCSD
2002-2007 Doris Duke Distinguished Clinical Scientist Award
2003 Member, Association of American Physicians
2003 Recipient, William Dameshek Prize, American Society of Hematology
2005 Cartwright Lectureship, University of Utah
2006 McCredie Lecturer, Leukemia and Lymphoma Society
2006 Councillor, American Society of Hematology
2007 Stanley J. Korsmeyer Award, American Society for Clinical Investigation
2008 Physician Mentor Recognition Award, Women Physicians Congress of the American Medical Association
2009 12th Annual Emil J Freireich Award, MD Anderson
2015 Member, National Academy of Medicine
2016 Champions for children Award, Moyer foundation

Related News

Additional Links & Information

Related Labs & Projects

View all labs & projects >
Dr. Gary Gilliland, MD, PhD

Contact Information

(206) 667-6767
(206) 667-5268
Additional contact

Mail Stop: D1-060